Global R&D Pipeline
My Favorite
Hot Targets:
CD38
Back
Total number of drugs
170
Phase II and later clinical stages
5.9%
Involving companies
232
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daratumumab/Hyaluronidase-fihj | Daratumumab/Hyaluronidase-fihj | Monoclonal antibody Enzyme | Neoplasms Immune System Diseases Cardiovascular Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other Diseases | CD38 inhibitors Hyaluronic acid modulators ADCC Antibody-dependent cellular phagocytosis (ADCP) effects Complement dependent cytotoxicity (CDC) effects | Janssen Global Services LLC Genmab, Inc. | Halozyme Therapeutics, Inc. Janssen Research & Development LLC Janssen-Cilag International NV Janssen Biotech, Inc. Janssen Pharmaceutical KK Johnson & Johnson Janssen-Cilag Pty Ltd. Janssen LP Xian-Janssen Pharmaceutical Ltd. | Approved | Approved | United States China European Union Japan Australia Iceland Liechtenstein Norway | 2017-07-17 | 2021-09-30 | Accelerated Approval（United States） Orphan Drug（United States） Orphan Drug（Japan） | - | - | - | - | Daratumumab/Hyaluronidase-fihj | - | - | detail > | |
| Isatuximab-IRFC | Isatuximab-IRFC | Monoclonal antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Endocrinology and Metabolic Disease Other Diseases | CD38 inhibitors | ImmunoGen, Inc. | Sanofi Genzyme Corp. Celgene Corp. Sanofi (China) Investment Co. Ltd. Bristol Myers Squibb Co. Sanofi-Aventis Deutschland GmbH Sanofi Winthrop Industrie SA Sanofi-Aventis Recherche & Développement SA Amgen, Inc. Sanofi-Aventis U.S. LLC Sanofi KK Sanofi-Aventis Canada, Inc. | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia United Arab Emirates Switzerland Iceland South Korea Liechtenstein Norway Russia | 2020-03-02 | 2025-01-08 | Orphan Drug（Australia） Orphan Drug（European Union） Orphan Drug（South Korea） Orphan Drug（United States） Priority Review（United States） | - | - | - | - | Isatuximab-IRFC | - | - | detail > | |
| 4SCAR-CD38 | 4SCAR-CD38 | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD38 inhibitors Cell replacements Gene transference | Shenzhen Geno-Immune Medical Institute | Shenzhen Geno-Immune Medical Institute | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | 4SCAR-CD38 | - | - | detail > | |
| Modakafusp Alfa | Modakafusp Alfa | Antibody fusion proteins | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases | CD38 inhibitors IFNAR agonists | Takeda Pharmaceutical Co., Ltd. | Takeda Development Center Americas, Inc. | Phase 2 | Discontinued (in Phase 2) | - | - | - | - | - | - | - | - | Modakafusp Alfa | - | - | detail > | |
| CART-38(Medical College of Soochow University) | CART-38(Medical College of Soochow University) | CAR-T | Neoplasms Hemic and Lymphatic Diseases | CD38 inhibitors | Medical College of Soochow University | Medical College of Soochow University | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | CART-38(Medical College of Soochow University) | - | - | detail > | |
| Lumrotatug | Lumrotatug | Monoclonal antibody | Immune System Diseases Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Urogenital Diseases Neoplasms Other Diseases | CD38 inhibitors | Keymed Biomedical Technology (Chengdu) Co., Ltd. | Keymed Biomedical Technology (Chengdu) Co., Ltd. Keymed Biosciences, Inc. First Affiliated Hospital Of Fujian Medical University | Phase 2 | Phase 2 | - | - | - | - | - | - | - | - | Lumrotatug | - | - | detail > | |
| Mezagitamab | Mezagitamab | Monoclonal antibody | Immune System Diseases Hemic and Lymphatic Diseases Neoplasms Urogenital Diseases | CD38 inhibitors ADCC | Takeda Pharmaceutical Co., Ltd. | Takeda Development Center Americas, Inc. Takeda Pharmaceutical Co., Ltd. Spera Pharma, Inc. Takeda (China) International Trading Co. Ltd. | Phase 3 | Phase 3 | - | - | - | Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United States） Paediatric investigation plan（European Union） Orphan Drug（Japan） | - | - | - | - | Mezagitamab | - | - | detail > | |
| Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen) | Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen) | Monoclonal antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases Skin and Musculoskeletal Diseases | CD38 inhibitors | Hangzhou Shangjian Biotechnology Co., Ltd. | Hangzhou Shangjian Biotechnology Co., Ltd. | Phase 3 | Phase 3 | - | - | - | - | - | - | - | - | Recombinant human anti-CD38 momoclonal antibody(Hangzhou Sumgen) | - | - | detail > | |
| Daratumumab | Daratumumab | Monoclonal antibody | Neoplasms Immune System Diseases Endocrinology and Metabolic Disease Hemic and Lymphatic Diseases Other Diseases Congenital Disorders Respiratory Diseases Mouth and Tooth Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | CD38 inhibitors ADCC Antibody-dependent cellular phagocytosis (ADCP) effects Complement dependent cytotoxicity (CDC) effects | Janssen Global Services LLC | Janssen-Cilag International NV Janssen Research & Development LLC Xian-Janssen Pharmaceutical Ltd. Janssen Pharmaceutica NV Janssen LP Janssen Pharmaceuticals, Inc. AbbVie, Inc. Genentech, Inc. Janssen-Cilag Pty Ltd. Janssen Biotech, Inc. Johnson & Johnson Consumer Health Care Switzerland Janssen R&D Ireland Share Participation Scheme Johnson & Johnson Pharmaceutical Research & Development LLC Janssen Scientific Affairs LLC Janssen Korea Ltd. Janssen-Cilag Ltd. Janssen Pharmaceutical KK Janssen, Inc. Johnson & Johnson (China) Investment Ltd. Janssen Cilag SpA | Approved | Approved | United States China European Union Japan Canada Australia Iceland South Korea Liechtenstein Norway | 2015-11-16 | 2019-07-04 | Accelerated Approval（United States） Breakthrough Therapy（United States） Fast Track（United States） Orphan Drug（European Union） Orphan Drug（United Kingdom） Orphan Drug（South Korea） Orphan Drug（United States） Priority Review（China） Priority Review（Japan） Conditional marketing approval（China） Orphan Drug（Japan） | - | - | - | - | Daratumumab | - | - | detail > | |
| Felzartamab | Felzartamab | Monoclonal antibody | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Urogenital Diseases Other Diseases Cardiovascular Diseases Skin and Musculoskeletal Diseases | CD38 inhibitors ADCC Antibody-dependent cellular phagocytosis (ADCP) effects | MorphoSys AG | TJ Biopharma Hangzhou Co Ltd Biogen, Inc. Human Immunology Biosciences, Inc. I-Mab Biopharma Hong Kong Ltd. MorphoSys AG I-MAB Biopharma (Shanghai) Co., Ltd. | NDA/BLA | NDA/BLA | - | - | - | Breakthrough Therapy（United States） Orphan Drug（European Union） Orphan Drug（United States） | - | - | - | - | Felzartamab | - | - | detail > |
Total 170 data
1
2
3
4
5
6
...
16
17
